NUCMED
The computed 12-month bankruptcy probability of NUCMED is 0.1% (very low). The 2024 annual accounts show equity of €51k and a net result of €133k. Equity is growing by ~18.8% per year across the filed fiscal years. Its solvency ranks better than 16% of 6565 sector peers (fiscal year 2024). The company has been active since 2015 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €51k |
| Net result | €133k |
| Better than sector | 16% |
| Active | 10 yrs |
Exceptional profile, strong across almost every axis.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 17.5% | 66.7% | |
| Net result | €133k | €46k | |
| Equity | €51k | €79k | |
| Gross operating margin | €251k | €78k | |
| Staff costs | €53k | €21k |
| Fiscal year | 2024 |
|---|---|
| Revenue | - |
| EBITDA | €196k |
| Net profit | €133k |
| Cash flow | €154k |
| Staff costs | €53k |
| Income taxes | €40k |
| Dividends | €127k |
| Total assets | €293k |
| Equity | €51k |
| Debt | €242k |
| of which ≤ 1y | €184k |
| of which > 1y | €58k |
| Working capital | €21k |
| Employees (FTE) | - |
| 2024 | |
|---|---|
| Current ratio | 1.11 |
| Quick ratio | 1.11 |
| Working capital ratio | 7.2% |
| Solvency | 17.5% |
| Debt / equity | 4.72 |
| Long-term debt ratio | 1.13 |
| Interest coverage | 117.88 |
| Gross margin | - |
| Net margin | - |
| ROA | 45.2% |
| ROE | 258.7% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €293k |
| Fixed assets | 21/28 | €88k |
| Tangible fixed assets | 22/27 | €88k |
| Financial fixed assets | 28 | €180 |
| Current assets | 29/58 | €205k |
| Amounts receivable within one year | 40/41 | €58k |
| Investments | 50/53 | €27k |
| Cash & bank | 54/58 | €112k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €293k |
| Equity | 10/15 | €51k |
| Contributions / capital | 10/11 | €12k |
| Reserves | 13 | €30k |
| Accumulated profits (losses) | 14 | €9k |
| Amounts payable | 17/49 | €242k |
| Amounts payable after one year | 17 | €58k |
| Amounts payable within one year | 42/48 | €184k |
| Trade debts payable within one year | 44 | €3k |
| Income statement | ||
| Gross operating margin | 9900 | €251k |
| Operating result | 9901 | €174k |
| Financial income | 75 | €188 |
| Financial charges | 65 | €2k |
| Result before taxes | 9903 | €173k |
| Income taxes | 67/77 | €40k |
| Net result for the period | 9904 | €133k |
| Result to be appropriated | 9905 | €133k |
| NACE primary | Human health(86220) |
| Legal form | Private limited company(610) |
| Incorporation | 31-08-2015 |
| Status | Active |
| Postal code | 1410 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 25762H0679/00A000 | Wallonia | 596 m² | 1 · 158 m² | 6.6 m · 2 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
28-12-2023 2 resigning
- Diana ENE, Bestuurder
- Ovidiu ENE, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Diana ENE",
"address": "Waterloo (1410) avenue des Sarcelles, 19",
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": "rechtzetting",
"subkind": "rectification",
"via_org": null,
"statutory": null,
"compensated": false,
"effective_date": null,
"evidence_quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de mettre fin \u00E0 la fonction des g\u00E9rants actuels mentionn\u00E9s ci-apr\u00E8s, et proc\u00E8de imm\u00E9diatement au renouvellement de leur nominations comme administrateur non statutaire pour une dur\u00E9e illimit\u00E9e : - Madame ENE Diana, domicili\u00E9e \u00E0 Waterloo (1410) avenue des Sarcelles, 19;",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Ovidiu ENE",
"address": "Waterloo (1410) avenue des Sarcelles, 19",
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": "rechtzetting",
"subkind": "rectification",
"via_org": null,
"statutory": null,
"compensated": false,
"effective_date": null,
"evidence_quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de mettre fin \u00E0 la fonction des g\u00E9rants actuels mentionn\u00E9s ci-apr\u00E8s, et proc\u00E8de imm\u00E9diatement au renouvellement de leur nominations comme administrateur non statutaire pour une dur\u00E9e illimit\u00E9e : - Madame ENE Diana, domicili\u00E9e \u00E0 Waterloo (1410) avenue des Sarcelles, 19;",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": "Simon WETS",
"firm_city": null,
"firm_name": "Benjamin Wets \u0026 Simon Wets, notaires associ\u00E9s",
"office_city": "Schaerbeek",
"is_associated": true
},
"act_meta": {
"language": "mixed",
"pub_date": "2023-12-28",
"filing_date": "2023-12-24",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decisions": [
{
"body": "algemene_vergadering",
"date": "2023-12-22",
"unanimous": true
}
],
"is_correction": false,
"subject_company": {
"kbo": "0635.886.072",
"name_full": "NUCMED",
"legal_form": "SRL"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [],
"corrected_publication_numac": null
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | NUCMED |
| AbbreviationFR | DrED |